Press Releases SoftOx Solutions

Stocks

SOFTX

NO0010811961

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 15:45:00 11/06/2026 BST			5-day change	1st Jan Change
0.1110 ^NOK	-4.97%		-2.63%	+26.42%

06-08	SoftOx Solutions AS announced that it expects to receive NOK 6.029468 million in funding from Long State Investments Limited	CI
06-05	SoftOx Solutions AS Enrolls First Participant In SIS-02 Phase 1 Clinical Study	CI

Press Releases

06-09	SoftOx Solutions AS: Notice of General Assembly	AQ
06-09	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
06-08	SoftOx Solutions AS: SIS-03 DOSE-ESCALATION PHASE COMPLETED AND INITIATION OF PROOF-OF-CONCEPT PHASE	AQ
06-05	SoftOx Solutions AS: FIRST PARTICIPANT ENROLLED IN BIODEFENCE-FOCUSED SIS-02 PHASE 1 CLINICAL STUDY	AQ
05-27	SoftOx Solutions AS: Annual Report 2025	AQ
04-21	SoftOx Solutions AS: New Share Capital	AQ
04-13	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
03-25	SoftOx Solutions AS: Fourth Quarter Report 2025	AQ
03-24	SoftOx Solutions AS: New Share Capital	AQ
03-11	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
03-03	SoftOx Solutions AS: First Subject Dosed in Combined Phase 2a Dose-Escalation and Proof-of-Concept Trial (SIS-03)	AQ
02-25	SoftOx Defense Solutions AS: HPRA Approves SIS-02 Phase 1 Trial, Strengthening Dual-Use and Preparedness Strategy	AQ
02-04	SoftOx Solutions AS: New Share Capital	AQ
01-23	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
12-29	SoftOx Solutions AS: Danish Medicines Agency Approves Phase 2a Trial for SoftOx Inhalation Solution	AQ
12-05	SoftOx Solutions AS: New Share Capital	AQ
11-28	SoftOx Solutions AS: Notice of Extraordinary General Assembly	AQ
11-28	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
11-26	SoftOx Solutions AS: Third Quarter Report 2025	AQ
11-14	SoftOx Solutions AS: GMP Drug Substance Successfully Manufactured – Key Milestone for CF and EDF Clinical Programs	PU
11-14	SoftOx Solutions AS: GMP Drug Substance Successfully Manufactured - Key Milestone for CF and EDF Clinical Programs	AQ
16/10/25	SoftOx Solutions AS: SoftOx submits Phase 1 Clinical Trial Application under the European Defence Fund (EDF) Program	AQ
13/10/25	SoftOx Solutions AS: New Share Capital	AQ
07/10/25	SoftOx Solutions AS: Private Placement resolved	AQ
03/10/25	SoftOx Solutions AS: New Share Capital	AQ